Events & Promotions
|
|
GMAT Club Daily Prep
Thank you for using the timer - this advanced tool can estimate your performance and suggest more practice questions. We have subscribed you to Daily Prep Questions via email.
Customized
for You
Track
Your Progress
Practice
Pays
Not interested in getting valuable practice questions and articles delivered to your email? No problem, unsubscribe here.
Apr 2512:30 AM EDT
-01:30 AM EDT
At one point, she believed GMAT wasn’t for her. After scoring 595, self-doubt crept in and she questioned her potential. But instead of quitting, she made the right strategic changes. The result? A remarkable comeback to 695. Check out how Saakshi did it.
Apr 2601:30 AM EDT
-02:30 AM EDT
Learn how Keshav, a Chartered Accountant, scored an impressive 705 on GMAT in just 30 days with GMATWhiz's expert guidance. In this video, he shares preparation tips and strategies that worked for him, including the mock, time management, and more.
Apr 2610:00 AM EDT
-11:00 AM EDT
The Target Test Prep course represents a quantum leap forward in GMAT preparation, a radical reinterpretation of the way that students should study. Try before you buy with a 5-day, full-access trial of the course for FREE!
Apr 2711:00 AM EDT
-12:00 PM EDT
Prefer video-based learning? The Target Test Prep OnDemand course is a one-of-a-kind video masterclass featuring 400 hours of lecture-style teaching by Scott Woodbury-Stewart, founder of Target Test Prep and one of the most accomplished GMAT instructors
Apr 2808:00 AM PDT
-11:00 AM PDT
Whether you are just beginning your MBA journey or fine-tuning your path to a 700+ score, GMAT Day is designed to give you a competitive edge.
May 0111:00 AM PDT
-12:00 PM PDT
Free- full-length test + 15 concept videos + 150+ short videos + study plan!
10 Feb 2026, 02:05
Kudos
Bookmarks
B
Be sure to select an answer first to save it in the Error Log before revealing the correct answer (OA)!
Difficulty:
95%
(hard)
Question Stats:
32% (02:21) correct
68%
(02:34)
wrong
based on 66
sessions
History
Date
Time
Result
Not Attempted Yet
Pharmaceutical company executive: The prevention of unfair advantages through unsafe products constitutes the primary goal behind government FDA safety regulations targeting pharmaceutical companies. Consumer protection and the maintenance of drug safety standards represent the core intentions of these regulatory measures, with public health outcomes being ultimately impacted as a result. Medical enterprises like pharmaceutical companies, however, center their operations around market competition, which itself functions as a fundamental mechanism for consumer protection. Profits from drug sales and market share expansion depend upon these companies’ ability to bring competitive products to consumers. Therefore, the pharmaceutical industry requires no additional FDA safety regulations for consumer protection to be adequately maintained amongst its enterprises.
The pharmaceutical company executive argues that FDA safety regulations are designed to prevent companies from gaining unfair advantages through unsafe products and to protect consumers. However, because pharmaceutical companies rely on market competition to drive product innovation and consumer choice, and since profit depends on competitive products, the executive concludes that no additional FDA safety regulations are necessary for the pharmaceutical industry.
The executive’s argument is most vulnerable to criticism on the grounds that it
A. fails to consider that an absence of additional regulations could lead to unsafe products entering the market
B. assumes that all pharmaceutical companies will always act in the best interest of consumers
C. overlooks the possibility that additional regulations could enhance product innovation
D. neglects the fact that competitive markets can sometimes fail to protect consumers adequately
E. takes for granted that FDA regulations have no impact on the cost of developing new drugs
The pharmaceutical company executive argues that FDA safety regulations are designed to prevent companies from gaining unfair advantages through unsafe products and to protect consumers. However, because pharmaceutical companies rely on market competition to drive product innovation and consumer choice, and since profit depends on competitive products, the executive concludes that no additional FDA safety regulations are necessary for the pharmaceutical industry.
The executive’s argument is most vulnerable to criticism on the grounds that it
A. fails to consider that an absence of additional regulations could lead to unsafe products entering the market
B. assumes that all pharmaceutical companies will always act in the best interest of consumers
C. overlooks the possibility that additional regulations could enhance product innovation
D. neglects the fact that competitive markets can sometimes fail to protect consumers adequately
E. takes for granted that FDA regulations have no impact on the cost of developing new drugs
10 Feb 2026, 11:15
Kudos
Bookmarks
isn't the primary goal of the FDA regulations to prevent the entry of unsafe products into the market, which is sunstantially covered by option A. on the other hand, option B talks about the pharma companies acting in the best interest of the consumers which admittedly is the indirect cause of the FDA, but through the scope and actions covered in option A?
10 Feb 2026, 20:43
Kudos
Bookmarks
(D) is the winner: The executive assumes that the "Fundamental Mechanism" (Market Competition) is perfect. If a competitive market ever fails to protect consumers—for example, if a company makes a huge profit by selling a dangerous drug before anyone realizes it's unsafe—then the executive's argument falls apart. (D) identifies this flaw: the market is not a perfect safety filter.
Why the others are "GMAT Traps":
A (The "Direct Weakener"): While true, (A) is a bit too simple for a "Flaw" question. It states the result of the flaw, but (D) describes the logical error in the executive's reasoning about how markets work.
B (The "Extreme" Trap): The executive doesn't necessarily assume companies act in the "best interest" of consumers; he assumes they act in their own interest (profit), which he claims leads to consumer protection. There is a subtle difference.
C (The "Innovation" Distractor): The argument is about Safety, not Innovation. Whether regulations help or hurt innovation is a separate issue from whether the market alone can keep drugs safe.
E (The "Cost" Out-of-Scope): The cost of developing drugs is never mentioned in the premises or the conclusion. This is a classic "real-world" distraction that doesn't touch the logic.
Why the others are "GMAT Traps":
A (The "Direct Weakener"): While true, (A) is a bit too simple for a "Flaw" question. It states the result of the flaw, but (D) describes the logical error in the executive's reasoning about how markets work.
B (The "Extreme" Trap): The executive doesn't necessarily assume companies act in the "best interest" of consumers; he assumes they act in their own interest (profit), which he claims leads to consumer protection. There is a subtle difference.
C (The "Innovation" Distractor): The argument is about Safety, not Innovation. Whether regulations help or hurt innovation is a separate issue from whether the market alone can keep drugs safe.
E (The "Cost" Out-of-Scope): The cost of developing drugs is never mentioned in the premises or the conclusion. This is a classic "real-world" distraction that doesn't touch the logic.
